RVMD
Revolution Medicines Inc
$
70.870
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
71.970
Open
70.070
VWAP
71.03
Vol
1.94M
Mkt Cap
13.70B
Low
69.5001
Amount
137.93M
EV/EBITDA(TTM)
--
Total Shares
164.99M
EV
12.03B
EV/OCF(TTM)
--
P/S(TTM)
--
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
--
--
-1.622
+23.83%
--
--
-1.572
+39.13%
--
--
-1.579
+40.94%
Estimates Revision
The market is revising Downward the revenue expectations for Revolution Medicines, Inc. (RVMD) for FY2025, with the revenue forecasts being adjusted by -98.8% over the past three months. During the same period, the stock price has changed by 91.49%.
Revenue Estimates for FY2025
Revise Downward
-98.8%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+6.48%
In Past 3 Month
Stock Price
Go Up
+91.49%
In Past 3 Month
18 Analyst Rating
12.54% Upside
Wall Street analysts forecast RVMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 79.76 USD with a low forecast of 67.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
0 Hold
0 Sell
Strong Buy
12.54% Upside
Current: 70.870
Low
67.00
Averages
79.76
High
104.00
12.54% Upside
Current: 70.870
Low
67.00
Averages
79.76
High
104.00
Wolfe Research
initiated
$75
2025-11-17
New
Reason
Wolfe Research
Price Target
$75
2025-11-17
New
initiated
Reason
Wolfe Research initiated coverage of Revolution Medicines with an Outperform rating and $75 price target. Revolution is "emerging as the clear leader in pancreatic cancer" with darxonrasib, the analyst tells investors. First-in-class is important in this space and the firm's analysis suggests the key second-line Phase 3 readout will hit next year, the analyst added.
JPMorgan
Brian Cheng
upgrade
$71 -> $82
2025-11-06
Reason
JPMorgan
Brian Cheng
Price Target
$71 -> $82
2025-11-06
upgrade
Reason
JPMorgan analyst Brian Cheng raised the firm's price target on Revolution Medicines to $82 from $71 and keeps an Overweight rating on the shares. JPMorgan also added the shares to its Analyst Focus List as a growth idea. While the company's Q3 report seems like a "non-event," it is making strategic moves to position the entire portfolio to "win in the long run,: the analyst tells investors in a research note.
H.C. Wainwright
Robert Burns
Buy
maintain
$72 -> $73
2025-11-06
Reason
H.C. Wainwright
Robert Burns
Price Target
$72 -> $73
2025-11-06
maintain
Buy
Reason
H.C. Wainwright analyst Robert Burns raised the firm's price target on Revolution Medicines to $73 from $72 and keeps a Buy rating on the shares following the Q3 report. The firm says new clinical data support the thesis that elironrasib addresses resistance mechanisms to first-generation KRAS inhibitors.
RBC Capital
Leonid Timashev
Outperform
initiated
$77
2025-11-03
Reason
RBC Capital
Leonid Timashev
Price Target
$77
2025-11-03
initiated
Outperform
Reason
RBC Capital analyst Leonid Timashev initiated coverage of Revolution Medicines with an Outperform rating and $77 price target. The firm believes Revolution is best positioned to execute on targeting RAS across oncology, given its "impressive" efficacy data, development lead, and pipeline. RBC thinks the company's Phase III readout in 2026 is "highly likely to hit."
Mizuho
Joseph Catanzaro
Outperform
initiated
$90
2025-10-20
Reason
Mizuho
Joseph Catanzaro
Price Target
$90
2025-10-20
initiated
Outperform
Reason
Mizuho analyst Joseph Catanzaro initiated coverage of Revolution Medicines with an Outperform rating and $90 price target. The firm believes the company's portfolio of RAS(ON) inhibitors are positioned to play "significant roles" in pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. Daraxonrasib in PDAC alone can drive "meaningful upside" in the shares, the analyst tells investors in a research note. Mizuho believes Revolution's portfolio could generate $10B in risk-adjusted sales in 2035.
Raymond James
Strong Buy
maintain
$72 -> $76
2025-10-17
Reason
Raymond James
Price Target
$72 -> $76
2025-10-17
maintain
Strong Buy
Reason
Raymond James raised the firm's price target on Revolution Medicines to $76 from $72 and keeps a Strong Buy rating on the shares. RevMed's daraxonrasib has been included in the FDA's Commisioner's National Priority Review Voucher program aimed at "Reducing downstream health care utilization, addressing a public health crisis, boosting domestic manufacturing, or increasing medication affordability with Most Favored Nation pricing," the analyst tells investors in a research note. The inclusion should truncate the time for daraxonrasib to reach the market in 2L RASmut pancreatic cancer, the firm says.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Revolution Medicines Inc (RVMD.O) is -10.57, compared to its 5-year average forward P/E of -9.53. For a more detailed relative valuation and DCF analysis to assess Revolution Medicines Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.53
Current PE
-10.57
Overvalued PE
-5.77
Undervalued PE
-13.30
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-6.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.75
Undervalued EV/EBITDA
-10.05
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2362.24
Current PS
0.00
Overvalued PS
7980.99
Undervalued PS
-3256.51
Financials
Annual
Quarterly
FY2025Q3
0.00
Total Revenue
FY2025Q3
YoY :
+79.42%
-315.27M
Operating Profit
FY2025Q3
YoY :
+95.28%
-305.21M
Net Income after Tax
FY2025Q3
YoY :
+71.28%
-1.61
EPS - Diluted
FY2025Q3
YoY :
+57.28%
-210.66M
Free Cash Flow
FY2025Q3
N/A
Gross Profit Margin - %
FY2025Q3
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q3
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 402.44% over the last month.
Sold
0-3
Months
14.7M
USD
17
3-6
Months
839.6K
USD
4
6-9
Months
914.9K
USD
6
0-12
Months
97.4K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
60.0M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
492.6K
Volume
3
0-12
Months
1.9M
Volume
6
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
801.2K
Volume
Months
0-12
6
7.0M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 402.44% over the last month.
Sold
0-3
Months
14.7M
USD
17
3-6
Months
839.6K
USD
4
6-9
Months
914.9K
USD
6
0-12
Months
97.4K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
60.0M
USD
Months
RVMD News & Events
Events Timeline
2025-11-05 (ET)
2025-11-05
16:20:10
Revolution Medicines reaffirms GAAP net loss forecast for FY25
2025-11-05
16:19:02
Revolution Medicines Announces Q3 EPS of $1.61, Exceeding Consensus Estimate of $1.41
2025-10-27 (ET)
2025-10-27
08:11:53
Revolution Medicines reveals that the U.S. FDA has awarded ODD to daraxonrasib.
Sign Up For More Events
Sign Up For More Events
News
4.5
11-17NASDAQ.COMSignificant ETF Inflows: XBI, RNA, RVMD, INSM
2.0
11-16BenzingaMaplebear, Tower Semiconductor, and Eli Lilly Rank Among the Top 10 Large-Cap Winners Last Week (Nov. 10-Nov. 14): Is Your Portfolio Included?
4.5
11-07NASDAQ.COMSignificant Withdrawals Observed in XBI, RNA, RVMD, INSM ETFs
Sign Up For More News
People Also Watch
RHI
Robert Half Inc
27.270
USD
+5.90%
LOAR
Loar Holdings Inc
64.480
USD
+0.69%
SUN
Sunoco LP
55.500
USD
+1.65%
JAZZ
Jazz Pharmaceuticals PLC
176.930
USD
+0.68%
SATS
EchoStar Corp
68.630
USD
+2.08%
AN
AutoNation Inc
206.970
USD
+4.39%
MNSO
MINISO Group Holding Ltd
19.570
USD
-0.10%
ONB
Old National Bancorp
21.100
USD
+4.20%
OTEX
Open Text Corp
33.090
USD
+1.60%
WEX
WEX Inc
146.050
USD
+4.43%
FAQ
What is Revolution Medicines Inc (RVMD) stock price today?
The current price of RVMD is 70.87 USD — it has increased 1.42 % in the last trading day.
What is Revolution Medicines Inc (RVMD)'s business?
What is the price predicton of RVMD Stock?
What is Revolution Medicines Inc (RVMD)'s revenue for the last quarter?
What is Revolution Medicines Inc (RVMD)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Revolution Medicines Inc (RVMD)'s fundamentals?
How many employees does Revolution Medicines Inc (RVMD). have?